Quantcast

Trimetazidine in conditions other than coronary disease, old drug, new tricks?

Research paper by Hai H Zou, Xing-Xing XX Zhu, Ya-Hui YH Ding, Qin-Yang QY Jin, Lin-Yan LY Qian, Dong-Sheng DS Huang, Xue-Jiang XJ Cen

Indexed on: 04 Mar '17Published on: 04 Mar '17Published in: International Journal of Cardiology



Abstract

Trimetazidine (TMZ) has traditionally been used as an anti-ischemic drug for coronary artery disease by selectively inhibiting the mitochondrial long-chain 3-ketoacyl-CoA thiolase. Recently, new applications for this therapy have been investigated. This article reviews alternative uses for TMZ in non-coronary artery diseases, such as non-ischemic cardiomyopathy, sepsis, myocardial dysfunction induced by anti-cancer drugs, diabetic cardiomyopathy and contrast-induced nephropathy.